The level of galectin-3 in the blood serum of patients with chronic hepatitis C
Abstract
Aim. to assess galectin-3 level in the serum of HCV patients according to the biochemical activity of hepatitis, liver fibrosis, in view of insulin resistance and overweight.
Materials and methods: The content of serum galectin-3 was detected in 78 patients with chronic hepatitis C in age from 20 to 55 years with oligosymptomatic course of the disease and minimally expressed liver fibrosis in most cases. We evaluated the association between the content of galectin-3 in the blood and metabolic disorders, biochemical activity of hepatitis and fibrosis of the liver.
Results: In patients with normal ALT levels (42% of the patients), the average level of galectin was 3.17 (1.23; 5.94) ng / ml. Elevated levels of gammaglobulin in blood was noted in 21 patients, 15 of them also had elevated levels of galectin-3. Patients infected with genotype 1b, galectin-3 was higher than other genotypes. With a high viral load (> 500,000 IU / mL), the average level of galectin-3 was higher than the lowest. One-third of patients with overweight levels of galectin-3 was higher than normal. MI was diagnosed in the majority (61.5%) examinees, and in these patients, there was an increase level of galectin-3. When comparing the levels of galectin in patients with varying degrees of fibrosis, significant differences were found only when F0 – F2 (p = 0,033).
Conclusion: The galectin-3 serum level was elevated in most patients with chronic hepatitis C. The maximum increase in galectin-3 was observed in patients with severe liver fibrosis (F 3). The connection between the level of galectin-3 and the metabolic syndrome components such as body mass index, and insulin resistance was found.
About the Authors
V. A. Kovalevа
The First Saint-Petersburg State Medical University named after academician I.P. Pavlov
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
N. S. Zhevnerova
The First Saint-Petersburg State Medical University named after academician I.P. Pavlov
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
T. V. Antonova
The First Saint-Petersburg State Medical University named after academician I.P. Pavlov
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
References
1. Rudakova AV Gusev DA, Uskov AN Lobzin Y. Antiviral therapy of chronic hepatitis C (genotype 1) in Russia: the cost and effectiveness. // Journal of Infectology. 2015-T.7, №1.- pp 91-98
2. Douglas MW, George J. Molecular mechanisms of insulin resistance in chronic hepatitis C. //World J Gastroenterol. 2009 Sept; 15(35): 4356-4364.
3. T.V. Antonovа, N.S. Zhevnerova, M.A. Romanovа, A.N. Kholodnaya, D.A.Lioznov
4. The contents of leptin and adiponectin in the blood in patients with chronic hepatitis C with disorders of carbohydrate and fat metabolism// J. Infectology Volume 6, number 3, 2014, р.71-78
5. Lonardo A., Ballestri S., Adinolfi L.E. et al. Hepatitis C virus-infected patients are ‘spared’ from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis // Can J Gastroenterol. – 2009. – Vol. 23, № 4. – P. 273-278.
6. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance.// Gastroenterology. 2004; 126:840-848.
7. Antonova TV Romanova MA Sergeeva EG Chronic hepatitis tit-C in patients with metabolic syndrome-IOM // Journal infektology- 2011, Vol.3, №3.- S.91-96
8. G.F. Trifonova, I.A. Levakova, D.D. Bolsun, S.L. Mukomolov 10. Acute and chronic hepatitis C in the Russian Federation in 1994-2013 years.// Infection and Immunity 2014, T. 4, number 3, pp. 267-274
9. Dumic J, Dabelic S, Flo gel M. Galectin-3: an open-ended story. //Biochim Byophys Acta 2006;1760:616-35
10. Chiariotti L, Salvatore P, Frunzio R, Bruni CB. Galectin genes: regulation of expression.// Glycoconj J. 2004;19:441-449.
11. Troncoso MF, Elola MT, Croci DO, Rabinovich GA. Integrating structure and function of ‘tandem-repeat’ galectins.// Front Biosci (Schol Ed). 2012;4:864-887.
12. Patterson R.J., Wang W., Wang J.L. Understanding the biochemical activities of galectin-1 and galectin-3 in the nucleus // Glycoconjugate J. – 2004. – №19. — С. 499-506.
13. Lui F.T., Patterson R.J., Wang J.L. Intracellular functions of galectins // Biochim Biophys Acta. – 2002; 1572: 263-273.
14. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis.// Proc Natl Acad Sci USA. 1996;93:6737-6742.
15. Yushkov P.V., Antonova S.S., Bartolazzi A. Galectin-3 in the differential diagnosis and prognosis of follicular thyroid tumors // Archives of Pathology. – 2004. – T. 66, № 2. – S. 39-42.
16. Califice S, Castronovo V, Van Den Br le F. Galectin-3 and cancer (Review). // Int.J.Oncol. 2004;25:983-992.
17. Fukumori T, Kanayama HO, Raz A. The role of galectin-3 in cancer drug resistance.// Drug Resist Updat. 2007;10:101-108.
18. Neil C. Henderson , Alison C. Mackinnon , Sarah L. Farnworth , Francoise Poirier, Francesco P. Russo et al.
19. Galectin-3 regulates myofibroblast activation and hepatic fibrosis // Proceedings of the National Academy of Sciences of the United States of America, National Academy of Sciences, 2006, 103 (13), pp.5060-65
20. Lakomkin SV, Skvortsov AA, Goryunov TW et al. Galectin-3 – A new marker of diagnosis and prognosis of chronic heart failure // Cardiology.- 2012. – №3. – С. 45-52.
21. Melnik AA Diagnostic value of galectin-3 as a biomarker for heart failure / A. A. Miller // Health Protection of Ukraine. -Kiїv 2015, N № 2.-S.32-33
22. Drapkina O.M., Deeva T.A. Prognostic Significance of galectin-3 measurement in patients with metabolic syndrome and non-alcoholic fatty liver disease//Cardiovascular Therapy and Prevention . 2015;14(5):40-47.
23. Carla Iacobini, Stefano Menini, Article: Galectin-3: An emerging all-out player in metabolic disorders and their complications// Glycobiology (Impact Factor: 3.15). 10/2014; 25(2).
24. Yilmaz H., Cakmac M., Inan O. Et al. Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor? //J. Endocrinolog Investig. – 2014;
25. Gyamdzhyan KA, Drapkina M., Maksimov L. Galectin-3: Clinical and prognostic value of determination in patients with chronic heart failure patients.// Journal of Cardiac Insufficiency. 2014; 82 (1): 51-55
26. Drapkina Oksana M., Dubolazova Yulia V. Application of biological markers in the diagnosis of diastolic heart failure // AG. 2011. №4. p 305-315
27. Ionin V.A., Listopad O.V., Nifontov S.E., Vasiljeva E.Y., Soboleva A.V., Belyaeva O.D., Baranova E.I. Galectin-3 in atients with metabolic syndrome and atrial fibrillation //Arterial Hypertension 2014;20(5):462-469.
Review
For citations:
Kovalevа V.A., Zhevnerova N.S., Antonova T.V. The level of galectin-3 in the blood serum of patients with chronic hepatitis C. Journal Infectology. 2016;8(2):85-91. (In Russ.)
Views:
685
.png)
.png)
Email this article 